Emergent BioSolutions gets $24M contract modification for CYFENDUS
Emergent BioSolutions (EBS) was awarded a contract modification valued at approximately $24 million for CYFENDUS®.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.